Paper Details

  1. Home
  2. Paper Details

Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.

Author: BlumRobert A, BradstreetThomas E, EvansJudith K, GarganoCynthia, LeeYih, MajumdarAnup K, PettyKevin J, ShadleCraig R

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Aprepitant is a drug used to prevent chemotherapy-induced nausea and vomiting. This study found that aprepitant had a modest, transient effect on the activity of certain enzymes involved in drug metabolism.
Paper Details　
Original Abstract of the Article :
The NK(1) receptor antagonist aprepitant (EMEND(R)), developed for use in combination with a 5HT(3) receptor antagonist and a corticosteroid to prevent highly emetogenic chemotherapy-induced nausea and vomiting (CINV), has been shown to have a moderate inhibitory effect as well as a possible inducti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/14973304

データ提供：米国国立医学図書館（NLM）

Aprepitant: A Journey Through the Complexities of Drug Interactions

Drug interactions are a common concern in healthcare, requiring careful consideration to ensure patient safety. This study investigates the potential inductive effects of aprepitant, a medication used to prevent nausea and vomiting associated with chemotherapy, on cytochrome P450 (CYP) 3A4 and 2C9 activity. The research utilizes a double-blind, randomized, placebo-controlled study to assess the impact of aprepitant on CYP3A4 and CYP2C9 activity, providing valuable insights for clinicians and pharmacists.

Aprepitant: A Modest Inducer of CYP3A4 and CYP2C9

The study demonstrates that aprepitant, while primarily known as an inhibitor of CYP3A4, also exhibits modest inductive effects on both CYP3A4 and CYP2C9. This finding highlights the complex and sometimes unexpected interactions that can occur between medications.

Navigating the Desert of Drug Interactions

Understanding potential drug interactions is crucial for ensuring patient safety. This research emphasizes the need for careful consideration of medication combinations, especially those involving medications that can influence drug metabolism.

Dr.Camel's Conclusion

This study explores the potential inductive effects of aprepitant on CYP3A4 and CYP2C9 activity. Much like a camel navigating a desert landscape, understanding drug interactions can help ensure a safe and effective treatment journey.

Date :
  1. Date Completed 2004-06-14
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

14973304

DOI: Digital Object Identifier

44/3/215

Related Literature

Article Analysis
・Effects of aprepitant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.